New survey: Will AZN’s MYSTIC trial succeed on overall survival* for either dual-I-O therapy or Imfinzi monotherapy? To vote, please go to https://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=1418 and select survey #167. *Final OS data from MYSTIC are expected in 1H18.